1319 - The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced no...
|Date||28 September 2012|
|Event||ESMO Congress 2012|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
W. Zhang, B. Chen
We retrospectively analyzed the relationship of EMT, IGF-1R and gefitinib efficacy in 53 NSCLC patients who accepted gefitinib as the second-line treatment. Compared with EMT (+), EMT (-) showed a higher ORR in both EGFR mutation subgroup (50.0% vs. 28.6%) and EGFR wild-type subgroup (20.0% vs. 4.5%), and a longer MST in EGFR wild-type subgroup (6 months vs. 3 months, P = 0.014). IGF-1R (-) showed a higher ORR tendency than IGF-1R (+) in EGFR mutation patients (54.6% vs. 30.0%) and EGFR wild-type patients (18.2% vs. 4.8%). EMT and IGF-1R are correlated with the efficacy of gefitinib as the second-line therapy for NSCLC, especially in patients with wild- type EGFR. (This work is supported by grants from the National Foundation of Natural Science, China. No. 81172225, No. 81101821 and No. 81000819)Disclosure
All authors have declared no conflicts of interest.